All In Biotech

Drug Trial Radar · NCT04223349

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

A Phase 1, Open-label Single-dose Crossover, and Double-blind Multiple-dose Parallel Group Study to Characterize the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of JNJ-70033093 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Jan 10, 2020

Primary completion

Apr 8, 2020

Study completion Apr 8, 2020

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and food on the PK of single-dose of JNJ-70033093 in healthy participants.

Conditions

  • Healthy

Interventions

  • JNJ-70033093Drug

    JNJ-70033093 capsules will be administered orally .

  • PlaceboDrug

    Matching placebo in capsule will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum Observed Analyte Concentration (Cmax) of JNJ-70033093Time frame: Up to Day 9
  2. Part 1: Time to Reach the Maximum Observed Analyte Concentration (Tmax) of JNJ-70033093Time frame: Up to Day 9
  3. Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to 12 Hours (AUC[0-12h]) of JNJ-70033093Time frame: 12 hours postdose (Day 1)
  4. Part 1: Apparent Terminal Elimination Half-life (t[1/2]) of JNJ-70033093Time frame: Up to Day 9
  5. Part 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-70033093Time frame: Up to Day 9
  6. Part 2: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC [0-last]) of JNJ-70033093Time frame: Up to Day 9
  7. Part 2: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-70033093Time frame: Up to Day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.